| Discovery | Replication | |||||||
---|---|---|---|---|---|---|---|---|---|
Benign tumors cohort I | Ovarian cancer cohort I | Endometrial cancer cohort I | Population controls I | Benign tumors cohort II | Ovarian cancer cohort II | Ovarian cancer cohort III | Endometrial cancer cohort | Population controls II | |
Number of women | 150 (SAL1) | 106 (SAL1) | 74 (SU1) | 399 (NSPHS) | 76 (SU2) | 160 (SU2) | 120 (UU) | 228 (UU) | 57 (UU) |
Age | |||||||||
Mean | 59.8 | 61.2 | 59.84 | 49.3 | 60.8 | 61.8 | 60.9 | 66.8 | 57.3 |
Median | 60 | 60 | 60 | 49 | 63 | 63 | 62 | 68 | 58 |
Range | 16–88 | 28–88 | 29–86 | 14–94 | 22–88 | 19–87 | 21–86 | 29–90 | 18–86 |
SD | 15.8 | 12.9 | 10.75974 | 20.3 | 14.5 | 11.9 | 12.9 | 10.5 | 14.2 |
P-value versus benign | NA | 0.870 | 0.003665 | 2.22E−08 | NA | 0.868 | 0.937 | 0.001 | 0.163 |
Ethnicity | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian |
Stage | |||||||||
I (I/IA/IB) | Â | 46 | 50 (0/41/9) | Â | Â | 35 | 10 | 109 (3/83/23) | Â |
II (II/IIA/IIB) | Â | 8 | 8 (8/0/0) | Â | Â | 9 | 3 | 13 (12/0/1) | Â |
III (III/IIIA/IIIB/IIIC/IIIC1/IIIC2) | Â | 47 | 10 (0/2/2/0/2/4) | Â | Â | 96 | 40 | 22 (1/4/4/5/1/7) | Â |
IV (IV/IVA/IVB) | Â | 5 | 6 (2/0/4) | Â | Â | 19 | 24 | 11 (5/0/6) | Â |
Classification unvailable | Â | Â | Â | Â | Â | 1 | 43 | 73 | Â |